GlassScriptPhysician profile
Yolande Marie Eckrich
NPI 1104336783
$3,755.37
in general payments reported to CMS, 2019-2025
38 companies · $944 in 2025
The $944 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $2,069 · 2023: $599 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $499.78 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $447.88 | 2022-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $378.80 | 2021-2023 | Austedo |
| Abbvie INC. | $283.05 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $209.18 | 2022-2025 | Spravato |
| Csl Behring | $191.18 | 2022-2023 | Hizentra, Privigen |
| Neurocrine Biosciences, INC. | $176.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $153.37 | 2021-2022 | |
| Ucb, INC. | $140.07 | 2022-2023 | Briviact |
| Vanda Pharmaceuticals INC. | $117.87 | 2022-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $117.59 | 2022-2023 | Reyvow, Emgality |
| Kyowa Kirin, INC. | $84.30 | 2022 | |
| Argenx US, INC. | $82.99 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $77.63 | 2022 | |
| Biogen, INC. | $74.67 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $65.56 | 2022-2025 | Auvelity |
| Ani Pharmaceuticals, INC. | $63.34 | 2022 | |
| Eisai INC. | $52.12 | 2025 | |
| Upsher-Smith Laboratories LLC | $48.31 | 2022 | |
| Alexion Pharmaceuticals, INC. | $47.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.36 | 2022-2023 | Trintellix |
| Lundbeck LLC | $44.16 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $37.55 | 2025 | Nuplazid |
| Avion Pharmaceuticals | $34.74 | 2022 | |
| Amgen INC. | $28.44 | 2022 | |
| Harmony Biosciences LLC | $27.47 | 2022 | |
| Mallinckrodt Hospital Products INC. | $27.02 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.69 | 2022 | |
| Pfizer INC. | $23.99 | 2025 | |
| Bausch Health US, LLC | $21.91 | 2022 | |
| Almatica Pharma LLC | $21.75 | 2023 | Loreev Xr |
| Merz Pharmaceuticals, LLC | $19.59 | 2025 | Xeomin, Inbrija |
| Neurelis, INC. | $18.11 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.62 | 2023 | Quviviq |
| Nevro Corp. | $13.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.73 | 2023 | Qelbree |
| Acorda Therapeutics, INC | $12.75 | 2021 | |
| Banner Life Sciences, LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolande Eckrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.